Resistance to linezolid. Are we surprised? How hard should we look?

Annals of Pharmacotherapy

Volumn 37, Issue 6, 2003, Pages 909-911

  Lomaestro, Ben M ^a  

^a ALBANY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; DRUG SENSITIVITY; DRUG USE; GRAM POSITIVE BACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

ACETAMIDES; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES;

EID: 0038485902     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D032     Document Type: Note

References (19)

1. Paladino JA. Linezolid: an oxazolidinone antimicrobial agent. Am J Health Syst Pharm 2002;59:2413-25.
2. Pillai SK, Sakoulas G, Wennersten C, Eliopoulos GM, Moellering RC, Ferraro MJ, et al. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J Infect Dis 2002;186:1603-7.
3. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2002;358:207-8.
4. Prystowsky J, Siddiqui F, Chosay J, Shinabarger DL, Millichap J, Peterson LR, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001;45:2154-6.
5. Wilson P, Andrews JA, Charlesworth R, Walesby R, Singer M, Farrell DJ, et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2003;51:186-8.
6. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant vancomycin-resistant Enterococcus faecium. N Engl J Med 2002;346:867-9.
7. Auckland C, Teare L, Cooke F, Kaufmann ME, Warner M, Jones G, et al. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J Antimicrob Chemother 2002;50:743-6.
8. Enne V, Howe RA, Walsh TR, Mutnick AH, Jones RN. Initial descriptions of linezolid resistance in S. epidermidis and Streptococcus oralis: report from the SENTRY Antimicrobial Surveillance Program (abstract LB-10). Presented at: The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27-30, 2002.
9. Bozdogan G, Patel MV, Gupte SV, De Souza NJ, Khorakiwala HF, Greenivas K, et al. Characterization of linezolid resistant mutants of Staphylococcus aureus and Streptococcus pneumoniae isolated from mouse in terms of 23S rRNA mutations (abstract 1609). Presented at: The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27-30, 2002.
10. Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann Pharmacother 2003;37:769-74. DOI 10.1345/aph.1C437.
11. Jones RN, Della-Latta P, Lee LV, Biedenbach DJ. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY antimicrobial surveillance network. Diagn Microbiol Infect Dis 2002;42:137-9.
12. Kahlmeter G, Brown DFJ. Resistance surveillance studies - comparability of results and quality assurance of methods. J Antimicrob Chemother 2002;50:775-7.
13. Mutnick AH, Biedenbach DJ, Turnidge JD, Jones RN. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis 2002;43:65-73.
14. Howe RA, Noel AR, Bowker KE, Bennett PM, Walsh TR, MacGowan AP. Linezolid resistance in Streptococcus pneumoniae (abstract 1611). Presented at: The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27-30, 2002.
15. Gupte SV, Sreenivas K, Nair S, Upadhyay DJ, Patel MV, Khorakiwala HF, et al. Selection of linezolid resistant mutants of MSSA, MRSA and pneumococci in murine infections (abstract 1610). Presented at: The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27-30, 2002.
16. Raad II, Hanna HA, Arbuckle RA, Chaiban G, Dvorak T, Hachem RY. Susceptibility patterns of vancomycin-resistant enterococci to quinupristin/dalfopristin and linezolid before and after clinical use (abstract 1134). Presented at: The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27-30, 2002.
17. Schroeder LK, Schreckenberger PC, Kelkar S, Quinn JP. Nosocomial super-infections due to ampicillin-sensitive, linezolid-resistant Enterococcus faecalis (abstract 1591). Presented at: The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27-30, 2002.
18. Jones RN, Low DE, Pfaller MA. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn Microbiol Infect Dis 1999;33:101-12.
19. Ballow CH, Jones RN, Biedenbach DJ. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis 2002;43:75-83.